Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to -$37.4 million.

  • Conmed's Cash from Financing Activities rose 2682.59% to -$37.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$135.8 million, marking a year-over-year increase of 1005.3%. This contributed to the annual value of -$135.8 million for FY2025, which is 1005.3% up from last year.
  • Conmed's Cash from Financing Activities amounted to -$37.4 million in Q4 2025, which was up 2682.59% from -$43.5 million recorded in Q3 2025.
  • Conmed's 5-year Cash from Financing Activities high stood at $159.1 million for Q2 2022, and its period low was -$58.8 million during Q4 2023.
  • Over the past 5 years, Conmed's median Cash from Financing Activities value was -$27.5 million (recorded in 2025), while the average stood at -$13.7 million.
  • In the last 5 years, Conmed's Cash from Financing Activities surged by 82016.75% in 2022 and then plummeted by 61034.3% in 2023.
  • Over the past 5 years, Conmed's Cash from Financing Activities (Quarter) stood at -$40.8 million in 2021, then soared by 128.23% to $11.5 million in 2022, then tumbled by 610.34% to -$58.8 million in 2023, then rose by 13.1% to -$51.1 million in 2024, then grew by 26.83% to -$37.4 million in 2025.
  • Its Cash from Financing Activities stands at -$37.4 million for Q4 2025, versus -$43.5 million for Q3 2025 and -$26.5 million for Q2 2025.